Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Need For Skilled Workforce A Key Issue In Countries Using mRNA Tech Transfer

Trials Of COVID-19 Vaccine From WHO Training Hub Could Begin Later This Year

Executive Summary

The World Health Organization is ramping up its efforts to provide lower-income countries with the ability to produce their own biological products, such as vaccines and monoclonal antibodies. A new biomanufacturing training facility is in the works, and more recipients of mRNA technology transfer for vaccine production are being chosen.

You may also be interested in...

MPP And WHO Name mRNA Technology Transfer Trainees

The World Health Organization and Medicines Patent Pool have identified 15 companies which will receive training and support through their COVID-19 mRNA vaccine technology transfer scheme.

G20 Health Threats Fund Needs More Clout, WHO’s C-TAP Underused

Numerous initiatives are under way to maximize equitable access to COVID-19 products around the world, but most have some drawbacks that need to be addressed if they are to meet their goals, according to the medicines access NGO, WEMOS.

WHO Biomanufacturing Training Hub Plan Offers Korea Chance On World Stage

South Korea welcomes WHO decision to designate the country as a global biomanufacturing training hub, citing various opportunities this could provide in fulfilling its goal of becoming a similar center of worldwide expertise in vaccines.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts